Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

5.0%

3 terminated/withdrawn out of 60 trials

Success Rate

81.3%

-5.3% vs industry average

Late-Stage Pipeline

30%

18 trials in Phase 3/4

Results Transparency

0%

0 of 13 completed trials have results

Key Signals

11 recruiting

Enrollment Performance

Analytics

N/A
21(46.7%)
Phase 4
16(35.6%)
Phase 2
5(11.1%)
Phase 3
2(4.4%)
Phase 1
1(2.2%)
45Total
N/A(21)
Phase 4(16)
Phase 2(5)
Phase 3(2)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (60)

Showing 20 of 60 trials
NCT06198699Not ApplicableRecruiting

Effects of Jing Si Herbal Tea on Quality of Life and Sleep in Dementia and Their Caregivers

Role: collaborator

NCT04496882Phase 4Active Not Recruiting

Chronic Hepatitis b Patients Switch to tAf After Discontinuation of Nucleoside Analogue

Role: collaborator

NCT06482411Completed

Risk Factors Affect Weight Loss Outcomes After Treatment.

Role: lead

NCT03443492Phase 2Completed

SLOG vs mFOLFIRINOX as the First-line Treatment in Locally Advanced Uncresectable or Metastatic Pancreatic Cancer

Role: collaborator

NCT03848260Not ApplicableSuspended

A Real-Time Magnetic Device Prototype for Temporary Management of Paralytic Lagophthalmos

Role: lead

NCT05125939Recruiting

Can Overall Adenoma Detection Rate Replace Screening Adenoma Detection Rate ? Multicenter Study

Role: collaborator

NCT07091942Recruiting

Curative Therapy After Atezolizumab and Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma

Role: collaborator

NCT05863208Not ApplicableRecruiting

Artificial Intelligence-assisted Colonoscopy With or Without Endocuff Vision

Role: lead

NCT03812016Not ApplicableRecruiting

A Feedback-enabled Magnetic Device for Temporary Management of Blepharoptosis

Role: lead

NCT06727864Phase 3Recruiting

Short Course Regimen in Low Risk Active Tuberculosis- a Multicenter, Randomized, Active-controlled, Trial

Role: collaborator

NCT03753074Phase 4Active Not Recruiting

Effectiveness of TAF in Reducing Clinical Events in CHB Patients Beyond Treatment Indications by Current Guidelines

Role: collaborator

NCT03024684Phase 4Active Not Recruiting

Statin for Preventing Hepatocellular Carcinoma Recurrence After Curative Treatment

Role: collaborator

NCT06476470Recruiting

Taiwan Interstitial Lung Disease Multi-center Investigation and Registry

Role: collaborator

NCT06447441Not ApplicableNot Yet Recruiting

Clinical Outcomes Of Mega-dosage Supplementations Of Cholecalciferol In Critically Ill Patients With Sepsis

Role: collaborator

NCT06460402Not ApplicableEnrolling By Invitation

Ice Therapy and Warm Baths for Hemorrhoidectomy Wound Care

Role: lead

NCT06456450Recruiting

Taiwan Severe Asthma Biologic Registry

Role: collaborator

NCT06420388Not ApplicableRecruiting

2% Lidocaine Gel in Reducing Postoperative Pain Following Haemorrhoidectomy

Role: lead

NCT05818072Not ApplicableRecruiting

The Prevalence, Risk Factors and Optimal Biopsy Protocol of BE

Role: lead

NCT05793268Not ApplicableActive Not Recruiting

Finite Versus Continuous Nucleos(t)Ide Analogues for Chronic Hepatitis B

Role: lead

NCT05768282Phase 4Unknown

Oral Prednisolone to Prevent Esophageal Stricture After RFA for Long-segment Esophageal Neoplasia

Role: lead